Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 1/20 | 0.61 |
| ▸ | CDC25B | P30305 | 1/20 | 0.61 |
| ▸ | CASP3 | P42574 | 1/20 | 0.61 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.54 |
| ▸ | PRKDC | P78527 | 2/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | ECE1 | P42892 | 1/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22186994 | 0.81 | PIK3CG (0.55) | APAF1CDC25BCASP3SENP8SENP7 | |
| SCHEMBL31061504 | 0.79 | PIK3CG (0.62) | APAF1CDC25BCASP3SENP8SENP7 | |
| SCHEMBL9704853 | 0.78 | APAF1 (0.63) | APAF1CDC25BCASP3SENP8SENP7 | |
| SCHEMBL13437617 | 0.77 | PIK3CG (0.63) | APAF1CDC25BCASP3SENP8SENP7 | |
| SCHEMBL3549520 | 0.77 | PIK3CG (0.63) | APAF1CDC25BCASP3SENP8SENP7 | |
| SCHEMBL9284616 | 0.77 | PIK3CG (0.63) | APAF1CDC25BCASP3SENP8SENP7 | |
| SCHEMBL4809435 | 0.77 | PIK3CA (0.67) | APAF1CDC25BCASP3SENP8SENP7 | |
| SCHEMBL19051444 | 0.76 | APAF1 (1.00) | APAF1CDC25BCASP3SENP8SENP7 | |
| SCHEMBL17473667 | 0.76 | PIK3CA (0.68) | APAF1CDC25BCASP3SENP8SENP7 | |
| SCHEMBL4808710 | 0.75 | PIK3CG (0.64) | APAF1CDC25BCASP3SENP8SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020136693-A1 | SUBSTITUTED QUINOLONE COMPOUNDS, THEIR USE IN THE TREATMENT OF CANCER, AND A METHOD FOR PREPARATION | UNIVERSITY OF PETRA (JO) | 2020-07-02 | — | — | WO | disclosed |
| EP-2231152-B1 | THIENOPYRANONES AS KINASE INHIBITORS | SIGNALRX PHARMACEUTICALS INC (US) | 2014-01-01 | — | — | EP | disclosed |
| US-20100130597-A1 | DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION | THE UNITED STATE OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICE (US) | 2010-05-27 | — | — | US | disclosed |
| EP-2170338-A2 | DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services (US) | 2010-04-07 | — | — | EP | disclosed |
| US-7572791-B2 | Therapeutic morpholino-substituted compounds | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-7572791-B2 | Therapeutic morpholino-substituted compounds | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-7572791-B2 | Therapeutic morpholino-substituted compounds | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| WO-2009008991-A2 | DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-12-18 | — | — | US | disclosed |
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | KINACIA PTY. LTD. (AU) | 2008-12-18 | — | — | US | disclosed |
| EP-1257537-B1 | THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| CN-1891693-A | Therapeutic morpholino-substituted compounds | KINACIA PTY LTD (AU) | 2007-01-10 | — | — | CN | disclosed |
| CN-1891699-A | Therapeutic morpholino-substituted compounds | KINACIA PTY LTD (AU) | 2007-01-10 | — | — | CN | disclosed |
| CN-1263743-C | Morpholino substituted compounds for treatment | KIENACIA CO LTD (AU) | 2006-07-12 | — | — | CN | disclosed |
| US-6977255-B2 | Therapeutic morpholino-substituted compounds | KINACIA PTY. LTD. (AU) | 2005-12-20 | — | — | US | disclosed |
| US-20050085471-A1 | Therapeutic morpholino-substituted compounds | KINACIA PTY LTD. | 2005-04-21 | — | — | US | disclosed |
| CN-1418195-A | Morpholino substituted compounds for treatment | KIENACIA CO LTD (AU) | 2003-05-14 | — | — | CN | disclosed |
| EP-1257537-A4 | THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS | KINACIA PTY LTD (AU) | 2003-04-23 | — | — | EP | disclosed |
| EP-1257537-A1 | THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS | Kinacia Pty Ltd (AU) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001053266-A1 | THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS | KINACIA PTY LTD. (AU) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130597-A1 | DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION | PRKAB1, PRKAG1, PRKAB2 | APAF1 2339/4885CDC25B 3324/4885CASP3 4543/4885 |
| US-20050085471-A1 | Therapeutic morpholino-substituted compounds | PIK3CA, PTK2, PDPK1 | APAF1 1808/4885CDC25B 1059/4885CASP3 1514/4885 |
| US-20080312233-A1 | Therapeutic Morpholino-Substituted Compounds | PIK3CA, PTK2, PDPK1 | APAF1 1833/4885CDC25B 1058/4885CASP3 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.